NSPR

AI Memo

InspireMD

As of 2026-09-10/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-10 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Potential FDA decisions on TCAR and CAS platforms • 2026-12-31

Base target: $1 / p=55% prob

Biggest risk

The bear case is that the recall reflects execution risk, the redesigned delivery system or pending platforms face regulatory delays, and the U.S. relaunch does not convert physician interest into durable procedure volume. No reliable post-print analyst revision or target-change dataset is available.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

The bull case rests on resilient international demand, positive early clinical outcomes, approximately $9 million of planned annual cost savings, and successful FDA decisions enabling a dual-platform U.S. relaunch. [#SEC-8K-2026-08-17]

Research note

Recommendation

—

Confidence

medium

As of

2026-09-10

Base target

p=55%

Bull target

p=20%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Recall-related U.S.
disruption remains the near-term overhang
International demand and early clinical evidence provide operating support

BearKey bullets

FDA approval timing or outcome could delay the planned U.S.
relaunch.
International growth and early clinical data have not yet demonstrated sustainable U.S.

WatchKey bullets

Potential FDA decisions on TCAR and CAS platforms

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=55%)

Target spread vs base: +112% / -59%

Scenario probabilities

Bull Target: $2 (p=20%)Base Target: $1 (p=55%)Bear Target: $0 (p=25%)

Commentary

News tone is mixed: the Q2 release highlighted 21% international growth, favorable early clinical outcomes, and a planned cost reset, but the recall caused negative reported U.S. revenue and delayed the U.S. commercial path. No dependable analyst revision or post-print price-reaction evidence is available, and social coverage is absent; confidence therefore remains moderate-low and event-driven.

As of 2026-09-10 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Recall-related U.S. disruption remains the near-term overhang
International demand and early clinical evidence provide operating support
SwitchGuard pivotal-trial enrollment

Scenarios

Bull Target (Scenario probability)

$2 / p=20% prob

Base Target (Scenario probability)

$1 / p=55% prob

Bear Target (Scenario probability)

$0 / p=25% prob

Analysis 2026-09-10 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.05

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Potential FDA decisions on TCAR and CAS platforms
Management said it continues to anticipate FDA decisions later in 2026 for the CGuard Prime 80 cm TCAR implant and the original CGuard platform for traditional carotid stenting. Timing and approval outcomes remain uncertain. [#SEC-8K-2026-08-17] [#EARNINGS-TRANSCRIPT-2026Q2]
Prob 55.00% • Move 55.00% • Priced-in 35.00%
EVENT2027-06-30
Redesigned delivery system submission and possible U.S. relaunch
Design changes to the recalled CGuard Prime 135 cm delivery system are undergoing validation and performance testing, with an FDA submission anticipated before year-end. [#SEC-8K-2026-08-17]
Prob 50.00% • Move 70.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Recall-related U.S. disruption remains the near-term overhang
2026-09-30
Q2 revenue was essentially flat year over year, while recall-related customer credits drove negative reported U.S. revenue and a gross loss. This is the clearest near-term sentiment risk. [#SEC-8K-2026-08-17] [#PR-EARNINGS-2026-08-17]
Prob 75% • Move -25% • Priced-in 70%

Long-term Catalysts

Months to a year

International demand and early clinical evidence provide operating support
2026-12-31
International revenue grew 21% year over year, while CGUARDIANS II reported 100% acute device success in 50 patients and no deaths, strokes, or myocardial infarctions at 30 days. These signals support the product thesis but do not remove regulatory and commercialization risk. [#SEC-8K-2026-08-17]
Prob 60% • Move 25% • Priced-in 45%
SwitchGuard pivotal-trial enrollment
2027-12-31
The company commenced enrollment in the CGUARDIANS III pivotal trial for its SwitchGuard neuroprotection system, creating a longer-duration pipeline milestone. [#SEC-8K-2026-08-17]
Prob 45% • Move 35% • Priced-in 20%

Risks

FDA approval timing or outcome could delay the planned U.S. relaunch.
International growth and early clinical data have not yet demonstrated sustainable U.S. commercial execution.
Recall-related credits and restructuring actions can distort near-term revenue and margins.
The company is a low-coverage microcap with limited independent estimate, target-revision, and market-reaction evidence.
The recalled delivery system requires successful validation, testing, and a new FDA submission.

Peers

Symbol	Summary
ARAY	Small same-sector device company offering closer size context, but its clinical and commercial profile is not directly comparable to InspireMD.
BSX	Large same-sector medtech company useful for category context, but its scale and portfolio breadth make it a weak valuation peer.
EW	Large same-sector medtech company useful for cardiovascular-device context, but materially mismatched in scale and diversification.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-10

Loading AI feed…

Symbol

Summary

ARAY

Small same-sector device company offering closer size context, but its clinical and commercial profile is not directly comparable to InspireMD.

BSX

Large same-sector medtech company useful for category context, but its scale and portfolio breadth make it a weak valuation peer.

Large same-sector medtech company useful for cardiovascular-device context, but materially mismatched in scale and diversification.